Location, location, location: Sub-cellular specific targeting of JNK as a novel therapy in breast cancer.

“三阴性”乳腺癌亚型是最具侵袭性的乳腺癌亚型，与其他亚型不同，没有专门针对这种亚型的药物。虽然已经确定了许多潜在的药物靶点，但由于它们在体内的其他有益作用，它们不能用于临床。我们现在正在部署我们的创新实验平台，专门针对一种被称为“JNK”的蛋白质的肿瘤促进功能，同时保留其有益功能。

The ‘triple negative’ breast cancer subtype is the most aggressive form of breast cancer, and unlike other subtypes, there are no drugs to specifically this subtype. While many potential drug targets have been identified, they cannot be utilised clinically because of other beneficial roles within the body. We are now deploying our innovative experimental platforms to specifically target the tumour promoting functions of a protein known as ‘JNK’, whilst retaining its beneficial functions.